Wells Fargo raised the firm’s price target on Mineralys Therapeutics (MLYS) to $50 from $26 and keeps an Overweight rating on the shares, reflecting increased probability in hypertension and confidence in competitive positioning. The firm sees the investment thesis revolving more around the M&A case over the next few quarters.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
- Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
- Mineralys announces new subgroup analyses from Phase 3 Launch-HTN trial
- Mineralys Therapeutics Announces Public Offering of Shares
- Mineralys Therapeutics 9.8M share Spot Secondary priced at $25.50